Cytokine gene variants and treatment outcome of cisplatin-based concomitant chemoradiotherapy in cervical cancer

• Published in: British journal of biomedical science Vol. 77; no. 2; pp. 81 - 86
• Main Authors: Kushwah, AS, Gupta, MK, Singh, R, Banerjee, M
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 02-04-2020; Taylor & Francis Ltd
• Subjects: Antineoplastic Agents - administration & dosage; Breast cancer; Cancer therapies; Carcinoma - drug therapy; Carcinoma - genetics; Carcinoma - mortality; Case-Control Studies; Cervical cancer; chemo radiation therapy (CRT); Chemoradiotherapy; Chemotherapy; Cisplatin; Cisplatin - administration & dosage; Cytokine gene variants; Cytokines; Cytokines - genetics; Female; genotypic analysis; Health risk assessment; Humans; IL-1β; India - epidemiology; Inflammation; Interleukin 1; Interleukin 1 receptors; Interleukin 6; Pharmacogenomic Testing; Polymerase chain reaction; Radiation therapy; Restriction fragment length polymorphism; Single-nucleotide polymorphism; Toxicity; Treatment Outcome; Tumor necrosis factor-α; Uterine cancer; Uterine Cervical Neoplasms - drug therapy; Uterine Cervical Neoplasms - genetics; Uterine Cervical Neoplasms - mortality; Uterus; India; genotypic analysis; Cytokine gene variants; chemo radiation therapy (CRT); cervical cancer; treatment outcome
• ISSN: 0967-4845; 2474-0896
• DOI: 10.1080/09674845.2020.1714164

Background: Cervical cancer is the second most common cancer among women after breast cancer. Its standard treatment is cisplatin-based concomitant chemoradiotherapy. Chronic inflammation in uterine cervix triggers both pro- and anti-inflammatory pathways. The unpredictability in toxicity and efficacy of treatment is a major challenge. We hypothesized a link between IL-1, IL-6 and TNF gene variants and treatment response.
Material & Methods: We genotyped 246 cervical cancer cases and 246 controls by PCR, PCR-RFLP and ARMS-PCR. Treatment and response were evaluated by RECIST criteria. Chemotherapy and radiation doses were same for all patients, whilst 48 were followed-up for 36 months after treatment.
Results: SNPs in IL-1RN, IL-1β, IL-6 and TNFα were linked with cervical cancer. Cases with certain allele combinations in IL-1RN, IL-1β, IL-6(-597A/G) and TNF-α showed odds ratios (95% CI) of up to 17.54 (2.7-24.08) for the presence of cervical cancer. Variant IL-1β (-511T/C) was linked to vital status but none were linked to overall survival.
Conclusion: Certain cytokine gene variants may help detect susceptibility to cervical cancer and predict response to chemoradiotherapy.